Prudential Financial
ORKA

Prudential Financial’s Oruka Therapeutics ORKA Stock Holding History

Prudential Financial’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.17M Buy
85,895
+79,855
+1,322% +$5.32M 0.01% 784
2026
Q1 		$296K Buy
+6,040
New +$210K ﹤0.01% 2029

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Prudential Financial's ORKA Position: Q2 2026 in Review

Prudential Financial increased its Oruka Therapeutics (ORKA) stake by 1,322% in Q2 2026, buying an estimated $5.32M and bringing the position to 85,895 shares worth $8.17M. The position accounts for 0.01% of the portfolio, ranked #784.

Prudential Financial first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Prudential Financial held 85,895 shares of Oruka Therapeutics worth $8.17M as of Q2 2026.
  • Prudential Financial bought 79,855 Oruka Therapeutics shares in Q2 2026, an estimated $5.32M.
  • Oruka Therapeutics made up 0.01% of Prudential Financial's portfolio in Q2 2026, its #784 holding.
  • Prudential Financial first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.